Qiu Yao, Shen Ting, Qiu Wei, Yang Hui
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology Visual Science, Guangzhou, 510060, China.
Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, 510630, Guangdong, China.
Heliyon. 2024 Jul 25;10(15):e35142. doi: 10.1016/j.heliyon.2024.e35142. eCollection 2024 Aug 15.
Neuromyelitis optica spectrum disorder-related optic neuritis (NMOSD-ON) is an autoimmune disease that affects the astrocytes. NMOSD-ON is one of the core clinical phenotypes of neuromyelitis optica spectrum disorder and its most-common initial symptom. NMOSD-ON is characterized by severe vision loss, poor prognosis and high recurrence, mainly affecting young and middle-aged individuals. It is a challenge to know how to improve patients' visual outcomes. In this report, we present a refractory case of NMOSD-ON treated with satralizumab after multiple conventional therapies proved ineffective. Satralizumab was found to effectively control relapses in this patient and visual improvement was found after 18 months of treatment. Given to that, satralizumab may have a potential longitudinal effect on visual improvement in NMOSD-ON.
视神经脊髓炎谱系障碍相关视神经炎（NMOSD-ON）是一种影响星形胶质细胞的自身免疫性疾病。NMOSD-ON是视神经脊髓炎谱系障碍的核心临床表型之一，也是其最常见的首发症状。NMOSD-ON的特征是严重视力丧失、预后差和高复发率，主要影响中青年个体。如何改善患者的视觉预后是一项挑战。在本报告中，我们展示了一例难治性NMOSD-ON病例，该病例在多种传统治疗无效后接受了萨特利珠单抗治疗。发现萨特利珠单抗可有效控制该患者的复发，并且在治疗18个月后发现视力有所改善。鉴于此，萨特利珠单抗可能对视神经脊髓炎谱系障碍相关视神经炎的视力改善具有潜在的长期效果。
